New open access policy analysis from Institute for Clinical and Economic Review (ICER) and NEWDIGS Initiative at Tufts Medical Center analyzes the challenges and potential policy options for paying for gene therapies.
Gene therapies offer transformative potential but bring three interconnected challenges: determining fair prices, managing clinical uncertainty, and addressing short-term budget impacts. This paper outlines policy reforms and market-based tools to help the US healthcare system overcome these challenges, ensuring more equitable and affordable access to gene therapies as they become more prevalent.
Share the research